257 related articles for article (PubMed ID: 23497305)
21. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
[TBL] [Abstract][Full Text] [Related]
22. Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
Peng Y; Chen Y; Zhang X; Yang Y; Cao D; Bi F; Li Z; Gou H
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1339-1346. PubMed ID: 29774414
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Dell'Aquila E; Cremolini C; Zeppola T; Lonardi S; Bergamo F; Masi G; Stellato M; Marmorino F; Schirripa M; Urbano F; Ronzoni M; Tomasello G; Zaniboni A; Racca P; Buonadonna A; Allegrini G; Fea E; Di Donato S; Chiara S; Tonini G; Tomcikova D; Boni L; Falcone A; Santini D
Ann Oncol; 2018 Apr; 29(4):924-930. PubMed ID: 29324972
[TBL] [Abstract][Full Text] [Related]
24. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
25. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Kim S; Dobi E; Jary M; Monnien F; Curtit E; Nguyen T; Lakkis Z; Heyd B; Fratte S; Cléau D; Lamfichekh N; Nerich V; Guiu B; Demarchi M; Borg C
BMC Cancer; 2013 Dec; 13():611. PubMed ID: 24373251
[TBL] [Abstract][Full Text] [Related]
26. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer.
Vedat Bayoglu I; Yildiz I; Varol U; Cokmert S; Kucukzeybek Y; Alacacioglu A; Demir L; Dirican A; Akyol M; Yildiz Y; Oktay Tarhan M
J BUON; 2015; 20(2):460-7. PubMed ID: 26011336
[TBL] [Abstract][Full Text] [Related]
27. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Di Bartolomeo M; Ciarlo A; Bertolini A; Barni S; Verusio C; Aitini E; Pietrantonio F; Iacovelli R; Dotti KF; Maggi C; Perrone F; Bajetta E
Eur J Cancer; 2015 Mar; 51(4):473-481. PubMed ID: 25637137
[TBL] [Abstract][Full Text] [Related]
28. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Giessen C; von Weikersthal LF; Hinke A; Stintzing S; Kullmann F; Vehling-Kaiser U; Mayerle J; Bangerter M; Denzlinger C; Sieber M; Teschendorf C; Freiberg-Richter J; Schulz C; Modest DP; Moosmann N; Aubele P; Heinemann V
BMC Cancer; 2011 Aug; 11():367. PubMed ID: 21861888
[TBL] [Abstract][Full Text] [Related]
29. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.
Kotaka M; Xu R; Muro K; Park YS; Morita S; Iwasa S; Uetake H; Nishina T; Nozawa H; Matsumoto H; Yamazaki K; Han SW; Wang W; Ahn JB; Deng Y; Cho SH; Ba Y; Lee KW; Zhang T; Satoh T; Buyse ME; Ryoo BY; Shen L; Sakamoto J; Kim TW
Chin J Cancer; 2016 Dec; 35(1):102. PubMed ID: 28007025
[TBL] [Abstract][Full Text] [Related]
30. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
[TBL] [Abstract][Full Text] [Related]
31. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
32. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Souglakos J; Ziras N; Kakolyris S; Boukovinas I; Kentepozidis N; Makrantonakis P; Xynogalos S; Christophyllakis Ch; Kouroussis Ch; Vamvakas L; Georgoulias V; Polyzos A
Br J Cancer; 2012 Jan; 106(3):453-9. PubMed ID: 22240792
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
34. A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
Hurwitz H; Mitchell EP; Cartwright T; Kwok A; Hu S; McKenna E; Patt YZ
Oncologist; 2012; 17(7):937-46. PubMed ID: 22622147
[TBL] [Abstract][Full Text] [Related]
35. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
[TBL] [Abstract][Full Text] [Related]
36. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
Maiello E; Di Maggio G; Cordio S; Cinieri S; Giuliani F; Pisconti S; Rinaldi A; Febbraro A; Latiano TP; Aieta M; Rossi A; Rizzi D; Di Maio M; Colucci G; Bordonaro R
Clin Colorectal Cancer; 2020 Jun; 19(2):109-115. PubMed ID: 32089455
[TBL] [Abstract][Full Text] [Related]
38. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
39. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
[TBL] [Abstract][Full Text] [Related]
40. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
Mishima H; Oba K; Sakamoto J; Muro K; Yoshino T; Hyodo I; Maehara Y
Jpn J Clin Oncol; 2012 Feb; 42(2):134-8. PubMed ID: 22167662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
